MBX Biosciences appoints Peter Radovich to board

His Class I term extends through the 2028 Annual Meeting, while the appointment includes an initial option award and cash compensation under MBX’s director policy.

Rhea-AI Filing Summary

MBX Biosciences, Inc. appointed Peter Radovich as a director effective October 20, 2026; the Board determined he is independent under Nasdaq listing standards. He is a Class I director serving until the Company’s 2028 Annual Meeting of Stockholders, and thereafter until a successor is elected and qualified or his earlier death, removal or resignation. The Board set its size at eight directors.

As a non-employee director, Radovich will receive cash compensation under the Non-Employee Director Compensation Policy and an initial non-qualified stock option to purchase 18,200 shares, to be granted on October 20, 2026. MBX is also entering into an indemnification agreement with him in the same form used with its other directors.

8-K Event Classification

2 items: 5.02, 9.01

2 items

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers Governance

Key personnel changes including departures, elections, or appointments of directors and executive officers.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, or exhibit attachments filed with this report.

Key Figures

Initial non-qualified stock option: 18,200 shares Board size: 8 directors Appointment effective date: October 20, 2026 +1 more

4 metrics

Initial non-qualified stock option 18,200 shares Award to be granted on October 20, 2026

Board size 8 directors Board size set in connection with the appointment

Appointment effective date October 20, 2026 Peter Radovich’s director appointment

Class I director term Until the 2028 Annual Meeting of Stockholders Peter Radovich’s term as a Class I director

Key Terms

non-qualified stock option, Class I director, indemnification agreement, Non-Employee Director Compensation Policy, +1 more

5 terms

non-qualified stock option financial

"initial award of a non-qualified stock option to purchase 18,200 shares"

A non-qualified stock option (NSO) is a contract that lets an employee or service provider buy company shares at a fixed price for a set period, like a voucher to purchase stock later at today’s price. It matters to investors because exercising NSOs creates ordinary income for the holder and can increase share count, affecting a company’s earnings and ownership mix; think of it as a future sale that can dilute existing shareholders and has immediate tax consequences for the recipient.

Class I director technical

"designated as a Class I director to serve until the Company’s 2028 Annual Meeting"

A class I director is a member of a company’s board who belongs to one of several groups whose terms expire in a specified year under a staggered election system; each class is elected on a different cycle so only a portion of the board faces re-election each year. This matters to investors because it affects how quickly control of the board can change, the company’s continuity and oversight, and the ease of mounting or defending against takeover efforts—think of a team where only some players are replaced each season rather than the whole roster at once.

indemnification agreement technical

"entering into an indemnification agreement with Mr. Radovich"

An indemnification agreement is a contract in which one party promises to cover losses, costs, or legal claims that another party might face, acting like a tailored safety net or private insurance policy. For investors, it matters because such agreements shift potential financial risk away from a company or its officers and onto the indemnifier, which can affect a company’s future liabilities, cash flow and how risky the investment appears during deal-making or litigation.

Non-Employee Director Compensation Policy financial

"Non-Employee Director Compensation Policy (as amended March 2026)"

Nominating and Corporate Governance Committee technical

"recommendation of the Nominating and Corporate Governance Committee"

A nominating and corporate governance committee is a group within a company's board of directors responsible for selecting and recommending individuals to serve as company leaders, such as directors or executives. They also develop and oversee policies to ensure the company is run fairly, ethically, and transparently. This committee matters to investors because it helps ensure the company is well-managed and guided by qualified, responsible leadership.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

Who joined MBX’s board and when?

MBX appointed Peter Radovich as a director effective October 20, 2026. The Board determined he is independent under Nasdaq listing standards, and he was designated a Class I director.

What compensation will Peter Radovich receive from MBX?

Radovich will receive an initial non-qualified stock option to purchase 18,200 shares, to be granted on October 20, 2026, and cash compensation under MBX’s Non-Employee Director Compensation Policy, as amended March 2026.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 10/22/2026 - 08:11 AM EDT Accepted by SEC EDGAR 10/22/2026 - 08:11 AM EDT Learn about SEC filing dates

false000177611100017761112026-10-202026-10-20

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): October 20, 2026

MBX Biosciences, Inc.

(Exact name of Registrant as Specified in Its Charter)

Delaware			001-42272	84-1882872
(State or Other Jurisdiction of Incorporation)			(Commission File Number)	(IRS Employer Identification No.)
11711 N. Meridian Street Suite 300
Carmel, Indiana				46032
(Address of Principal Executive Offices)				(Zip Code)

Registrant’s Telephone Number, Including Area Code: (317) 659-0200

Not Applicable

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock, $0.0001 par value per share		MBX		Nasdaq Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

Effective as of October 20, 2026, the board of directors (the “Board”) of MBX Biosciences, Inc. (the “Company”), upon the recommendation of the Nominating and Corporate Governance Committee of the Board (the “NCG Committee”), appointed Peter Radovich as a director of the Company. The Board determined that Mr. Radovich is independent under the applicable listing standards of The Nasdaq Stock Market (“Nasdaq”).

Mr. Radovich has been designated as a Class I director to serve until the Company’s 2028 Annual Meeting of Stockholders, in accordance with the Company’s amended and restated by-laws and to serve thereafter until his successor has been duly elected and qualified or until his earlier death, removal or resignation. In connection with the appointment, the Board set the size of the Board at eight directors.

In connection with his appointment as a non-employee director, Mr. Radovich will receive compensation, including an initial award of a non-qualified stock option to purchase 18,200 shares of the Company’s common stock, to be granted on the appointment date of October 20, 2026. In addition, Mr. Radovich will receive cash compensation for his Board service, in accordance with the Company’s Non-Employee Director Compensation Policy (as amended March 2026), which was previously described in the Company’s Annual Proxy Statement for the period ending December 31, 2025, filed with the Securities and Exchange Commission on April 22, 2026. In addition, in connection with his election, the Company is entering into an indemnification agreement with Mr. Radovich in the same form as used with the Company’s other directors.

There are no arrangements or understandings between Mr. Radovich and any other persons pursuant to which he was selected as a director of the Company, and there are no transactions in which Mr. Radovich has an interest requiring disclosure under Item 404(a) of Regulation S-K.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

Exhibit No.	Description
104	Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

			MBX BIOSCIENCES, INC.
Date:	October 22, 2026	By:	/s/ Steven L. Hoerter
			President and Chief Executive Officer (Principal Executive Officer)

Filing Exhibits & Attachments

1 document

Other Documents

• EX-101 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT 26.3 KB